This promotional website is for UK healthcare professionals involved in the care of patients with cancer. Adverse event reporting information can be found below.
UK-VNCAML-240003 | April 2024.
Dosing & TLS prophylaxis
(tumour lysis syndrome)
VENCLYXTO® in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly-diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.1
Starting treatment for AML with VENCLYXTO,
a BCL-2 inhibitor, in combination with AZACITIDINE1
UK-VNCAML-240063 | April 2024.
You are advised to read the Prescribing Information and Summary of Product Characteristics (GB SmPC; NI SmPC) to evaluate patient suitability for VENCLYXTO.
Adverse events should be reported.
Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
